Boston Scientific Corporation $BSX Shares Acquired by Baird Financial Group Inc.

Baird Financial Group Inc. boosted its position in Boston Scientific Corporation (NYSE:BSX) by 13.4% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 273,534 shares of the medical equipment provider’s stock after purchasing an additional 32,417 shares during the quarter. Baird Financial Group Inc.’s holdings in Boston Scientific were worth $29,380,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. 1248 Management LLC purchased a new stake in shares of Boston Scientific during the first quarter worth about $26,000. Y.D. More Investments Ltd purchased a new position in shares of Boston Scientific during the first quarter valued at approximately $27,000. Sound Income Strategies LLC boosted its position in Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 120 shares during the last quarter. Kilter Group LLC purchased a new stake in Boston Scientific in the 2nd quarter worth approximately $30,000. Finally, Princeton Global Asset Management LLC purchased a new stake in Boston Scientific in the 2nd quarter worth approximately $32,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Trading Down 0.3%

Shares of BSX stock opened at $97.46 on Friday. Boston Scientific Corporation has a fifty-two week low of $85.98 and a fifty-two week high of $109.50. The firm’s 50 day moving average price is $99.27 and its two-hundred day moving average price is $102.07. The stock has a market cap of $144.48 billion, a price-to-earnings ratio of 52.12, a price-to-earnings-growth ratio of 1.97 and a beta of 0.67. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The business had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The business’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Wells Fargo & Company increased their price target on Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. Needham & Company LLC reiterated a “buy” rating and set a $121.00 target price on shares of Boston Scientific in a research report on Friday, October 17th. Royal Bank Of Canada reissued an “outperform” rating and issued a $125.00 price target on shares of Boston Scientific in a research note on Monday, September 29th. Leerink Partners lifted their price target on Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday, October 1st. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $123.77.

Insider Buying and Selling

In related news, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the transaction, the director owned 24,134 shares in the company, valued at $2,371,889.52. This represents a 34.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 143,095 shares of company stock valued at $14,228,950. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.